New Russian drug can replace a number of strong chemotherapy therapies

1 April 2019

Russian Venture Company (RVC), a state-operated high-tech company specializing on the implementation of projects in the field of pharmaceuticals, has announced plans to invest more than $10 million in the development of a new device and a drug for the treatment of tuberculosis and cancer, reports The Pharma Letter’s local correspondent.

Currently, the company finishes the development of a special inhaler and nano-aerosol for the treatment of patients who suffer from tuberculosis and oncology. The use of the new development from RVC reduces toxicity of strong drugs taken by patients.

According to an official spokesman of RVC, thanks to the built-in fingerprint identifier, the new device will be able to determine who uses it and what dose of drug is needed. Moreover, it will be capable of monitoring the receipt of the required amount of a drug by the patient, sending the data to the doctor about the intake schedule and the dose taken. It is assumed, that the new nano-aerosol can replace a number of strong drugs in chemotherapy programs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK